Metastasis is a multistep process in which primary tumor cells are re-established at distant organ sites and develop into secondary tumors. It accounts for the majority of deaths among patients with solid tumors, necessitating better elucidation of the mechanisms involved and development of new therapies to specifically block this process. One of the initiating events implicated in the onset of metastasis is the epithelial-to-mesenchymal transition (EMT), a cellular process in which polarized epithelial cells change shape into motile mesenchymal cells. This issue's Molecular Medicine Select highlights recent work in an ongoing effort to better understand the molecular mechanisms that regulate tumor metastasis and EMT.
Metastasis Regulation Goes Global
Metastasis is a multistep process requiring primary tumor cells to invade surrounding tissue, to enter and survive in the circulatory system, and to extravasate into distant organ sites, where they can grow into secondary tumors. It is thought that metastatic cells undergo drastic changes in their gene expression profiles, but how tumor cells acquire such global gene expression changes in the first place is unclear. To address this question, Han et al. (2008) investigated the role of a nuclear protein called SATB1, which acts as a ''genome organizer,'' providing a nuclear architecture onto which a large number of genomic loci are tethered and to which chromatin remodeling enzymes and transcription factors are recruited. Increased expression of SATB1 in breast cancer cell lines and in human breast cancer cells correlates with aggressive tumor phenotypes and shorter patient survival times. Depletion of SATB1 in highly aggressive breast cancer cells by RNA interference resulted in the altered expression of hundreds of genes and restoration of acinar polarity to the tumor cells with a consequent decrease in tumor growth and metastasis. Meanwhile, enforced expression of SATB1 in a nonmetastatic breast tumor cell line promoted the metastasis of the less-aggressive tumor cells. Comparing gene expression profiles revealed that SATB1 upregulates metastasis promoting genes and downregulates metastasis suppressor genes involved in cell adhesion, cell-cell junction formation, cell cycle regulation, cellular signaling, and apoptosis. The authors then show that SATB1, when bound to the genomic loci of target genes, assembles chromatin modifying proteins resulting in epigenetic modifications and corresponding changes in gene expression. Thus, in primary breast tumor cells, SATB1-mediated gene expression alterations may enable cells to become metastatic. This finding suggests that SATB1 expression may have value as a prognostic marker of metastatic potential even in early-stage breast cancer, and may also represent a new therapeutic target for treating metastatic breast tumors. H.-J. Han et al. (2008) . Nature. 452, [187] [188] [189] [190] [191] [192] [193] miRNAs Get into the EMT Business .
Single-stranded small RNAs 18-24 nt in length are called microRNAs (miRNAs). These miRNAs are known to be involved in the regulation of many key processes in the cell through posttranscriptional regulation of gene expression. Gregory et al. (2008) were interested in the possibility that miRNAs could regulate EMT, which is known to be an initiating event in tumor metastasis. Using an in vitro model in which epithelial cells are induced to undergo EMT by the growth factor TGFb, these researchers observed downregulation of all five members of the miRNA-200 family as well as miR-205. When they ectopically expressed these miRNAs in their epithelial cell cultures, they found that miR-200 family members could block TGFb-induced EMT. In addition, these miRNAs could reverse EMT in a process referred to as mesenchymal-to-epithelial transition (MET). Using a target prediction program, they identified the ZEB1 and SIP1 genes as potential targets of the miR-200 family and miR-205. The transcription factors ZEB1 and SIP1 have been implicated in repression of the gene encoding the epithelial adhesion molecule, E-cadherin, and in promotion of EMT and tumor metastasis. The investigators found that endogenous miR-200 family members and miR-205 cooperatively repressed ZEB1 and SIP1 expression. These data are further corroborated by the finding that expression of these miRNAs is repressed in invasive breast cancer cell lines exhibiting a mesenchymal phenotype and in regions of breast tumor tissue that do not express E-cadherin. Together, these findings suggest an important role for the miR-200 family and miR-205 in the silencing of ZEB1 and SIP1 and hence in preventing EMT and the initiation of tumor metastasis. P. A. Gregory et al. (2008 ). Nat. Cell Biol. Published online March 30, 2008 . 10.1038 .And So Does the Natural Antisense Transcript
The transcription factor Snail plays an essential role in promoting EMT and can repress expression of epithelial cell genes such as those encoding E-cadherin either directly or indirectly, activating the transcriptional regulators ZEB1 and its relative SIP1. Although Snail can transcriptionally activate ZEB1, SIP1 appears to be regulated at the posttranscriptional level. While investigating the regulation of SIP1 by Snail, Beltran et al. (2008) discovered an uncommon regulatory mechanism involving a natural antisense transcript or NAT. This natural antisense transcript is known to originate from a spliced SIP1 messenger RNA generated by transcription of this gene in the opposite direction. However, the regulation of NAT and its precise function remain unclear. The new study by Beltran et al. reveals that Snail can upregulate NAT expression and that NAT then binds to Antisense inhibition of miR-205 and miR-200 family members blocks expression of the adhesion molecule E-cadherin (left) and drives cells into the EMT with loss of E-cadherin (right). Photo courtesy of P. Gregory. the 5 0 UTR of SIP1, preventing its processing by the spliceosome machinery. Translation of SIP1 is dependent on the intact 5 0 UTR containing an internal ribosome entry site. The authors show that the overexpression of NAT regulates SIP1 protein, which results in the repression of E-cadherin, a necessary event for the promotion of EMT. This study, and also that by Gregory et al., illustrate the sophisticated mechanisms that have evolved for fine-tuning EMT, a tightly controlled process that when dysregulated leads to catastrophic outcomes for the organism. M. Beltran et al. (2008) . Genes Dev. 22, 756-769.
The Mitochondria and Metastasis
Mitochondrial DNA (mtDNA) is considered to be the major cellular target of chemical carcinogens, and mtDNA mutations occur with high frequency. To study whether mtDNA mutations play a role in metastatic potential, Ishikawa et al. (2008) used a cytoplasmic hybrid (cybrid) technology for ''swapping'' mtDNA between cells. In a metastasis mouse model, the authors found that metastatic potential was conferred to a poorly metastatic cell line by the mtDNA from a highly metastatic mouse cell line. In the highly metastatic cell lines, they further identified two mtDNA mutations within the gene encoding NADH dehydrogenase subunit 6, which are responsible for mitochondrial respiratory complex I deficiency. This mitochondrial dysfunction is associated with overproduction of reactive oxygen species (ROS) and upregulation of metastasis-associated genes including those encoding MCL-1, HIF-1a, and VEGF. Treatment with ROS scavengers led to downregulation of MCL-1 and suppression of metastatic activity. When the same experiments were performed in two human cell lines, similar results were observed. Taken together, these data suggest that mutated mtDNA may contribute to metastatic potential through ROS overproduction and upregulation of genes that promote metastasis. In addition to assigning a new role for mtDNA in mediating metastatic potential, this study also suggests that ROS scavengers may have therapeutic potential as inhibitors of metastasis. K. Ishikawa et al. (2008) . Science. Published online April 3, 2008 . 10.1126 
Stopping Metastasis in Its Lymphatic Tracks
Although metastasis of solid tumors accounts for the majority of deaths among cancer patients, there are currently no clinical therapies to specifically block metastasis. Metastasis occurs through the dissemination of tumor cells via the circulatory system. Recent evidence from mouse cancer models as well as from pathological analysis of patient tumor samples suggests that growth of lymphatic vessels (lymphangiogenesis) in or close to tumors is also associated with metastasis. Normal lymphangiogenesis is mediated by the secreted growth factor VEGFC (which is overexpressed in tumor cells). VEGFC induces the growth of lymphatic vessels by activating the VEGFC receptor expressed in the endothelial cells lining the vessels. In an effort to better understand this process, Bagri and colleagues (2008) have developed an antibody to the VEGFC coreceptor, Neuropilin-2 (Nrp2), better known as a receptor in axon guidance. They show that this antibody blocks VEGFC from binding to its receptor and inhibits its downstream effects on lymphatic endothelial cell migration, in part independently of VEGF receptor activation, as well as formation of new functional lymphatic vessels. Importantly, when tumors were treated with this antibody, formation of functional tumor associated lymphatics was blocked, but established lymphatics in normal adult mice were unaffected. Treatment with the anti-Nrp2 antibody functionally reduced distant tumor metastases in a mouse mammary carcinoma model without affecting growth of the primary tumor, likely by blocking spread of the primary tumor cells via the lymphatic system. This study reveals new insights into the mechanisms of tumor lymphangiogenesis and how this process may contribute to metastasis. The anti-Nrp2 antibody may therefore have potential in preventing the early steps of metastasis via the lymphatic system. M. Caunt et al. (2008) . Cancer Cell 13, 331-342.
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Electron microscopic images of mitochondria in poorly (left) and highly (right) metastatic mouse lung tumor cells. Photo courtesy of K. Nakada.
Cancer cells leave the primary tumor (left) and enter lymphatic vessels (green) eventually entering the blood (red); from there, they metastasize to distant organs in this case the lung (metastases, dark gray). Image courtesy of A. Questell.
